Klick Health's recent acquisition of Oxford PharmaGenesis reflects that shift. “Clearly for a lot of reasons that have been ...

Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing ...

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia – a digital ...

When pharmaphorum last spoke with MRM Health founder and CEO Sam Possemiers at JP Morgan, he told us about his company’s microbiome-based therapy for ulcerative colitis. At LSX USA in Boston last ...

As antibody-drug conjugates (ADCs) continue to establish themselves as a cornerstone of modern oncology, breakthrough ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...

The UK government has said it will accept all 44 recommendations made in a recently published report on using AI tools in the NHS, including continual monitoring after deployment. This morning, the ...

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments. In a new ...

This is not simply a broader role for Market Access. It is an emerging leadership capability for the healthcare business.

The governor of New York has said that rising cases of measles constitute a "statewide disaster emergency," the first such ...

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

Shares in Vaxcyte have rocketed on the revelation of phase 3 trial data for its pneumococcal vaccine (PCV) candidate VAX-31, ...